A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany

  • Breast Cancer
Trial Status:


This trial runs in
  • Augsburg
  • Bamberg
  • Bayreuth
  • Bergisch Gladbach
  • Berlin
  • Bocholt
  • Bochum
  • Bonn
  • Coburg
  • Dessau-Roßlau
  • Dortmund
  • Dresden
  • Duisburg
  • Düren
  • Düsseldorf
  • Erlangen
  • Frankfurt am Main
  • Freiburg im Breisgau
  • Friedrichshafen
  • Gummersbach
  • Göppingen
  • Göttingen
  • Hagen
  • Halle (Saale)
  • Hamburg
  • Hamm
  • Hanau
  • Hannover
  • Heidelberg
  • Hildesheim
  • Ingolstadt
  • Jena
  • Karlsruhe
  • Kassel
  • Kiel
  • Konstanz
  • Köln
  • Lübeck
  • Magdeburg
  • Mannheim
  • Mühlhausen Thüringen
  • München
  • Münster
  • Neubrandenburg
  • Oberhausen
  • Osnabrück
  • Recklinghausen
  • Reutlingen
  • Rotenburg (Wümme)
  • Schweinfurt
  • Schwerin
  • Stendal
  • Stuttgart
  • Weiden in der Oberpfalz
Trial Identifier:

NCT02666261 ML29763

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This non-interventional study will collect data from routine diagnostics on HER2 testing of breast cancer in Germany.

      Hoffmann-La Roche Sponsor
      NCT02666261 , ML29763 Trial Identifier
      Breast Cancer Condition
      Official Title

      A Non-interventional Study on the Epidemiology and Testing of HER2 in Breast Cancer in Germany

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Samples derived from men and women of age greater than or equal to (>/=) 18 years
      • Samples derived from participants with any stage of histologically confirmed invasive breast cancer with HER2 diagnostics performed within routine (histo-)pathological workup or
      • (Histo-)Pathological work-up of the tumor sample as at or after start of this study
      • Available information on the year of birth of the participant
      • No pre-selection of tumor samples is allowed. Tumor samples have to be documented consecutively in the order of their (histo-)pathological work-up.
      Exclusion Criteria
      • Sample derived from participants with any stage of breast cancer with no HER2 diagnostics performed at the time of routine (histo-)pathological work-up.
      • Samples derived prior to the start of this study.

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now